{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:41:40Z","timestamp":1786869700093,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bioorg.2022.106051","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T22:40:29Z","timestamp":1659652829000},"page":"106051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity"],"prefix":"10.1016","volume":"129","author":[{"given":"Yongjin","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.106051_b0005","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/cdd.2012.90","article-title":"TRAIL induces necroptosis involving RIPK1\/RIPK3-dependent PARP-1 activation","volume":"19","author":"Jouan-Lanhouet","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2022.106051_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.immuni.2016.06.007","article-title":"RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4","volume":"45","author":"Najjar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2022.106051_b0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/SHK.0b013e31820b2db1","article-title":"The dual functions of receptor interacting protein 1 in fas-induced hepatocyte death during sepsis","volume":"35","author":"McNeal","year":"2011","journal-title":"Shock"},{"key":"10.1016\/j.bioorg.2022.106051_b0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature20559","article-title":"RIPK1 inhibits ZBP1-driven necroptosis during development","volume":"540","author":"Newton","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106051_b0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2022.106051_b0030","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","article-title":"RIP kinases as modulators of inflammation and immunity","volume":"19","author":"He","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2022.106051_b0035","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.cell.2008.12.004","article-title":"Necroptosis: a specialized pathway of programmed necrosis","volume":"135","author":"Galluzzi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2022.106051_b0040","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2022.106051_b0045","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.1901179116","article-title":"Targeting RIPK1 for the treatment of human diseases","volume":"116","author":"Degterev","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2022.106051_b0050","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/acs.jmedchem.9b01317","article-title":"Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives","volume":"63","author":"Zhuang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molcel.2014.11.001","article-title":"The two faces of receptor interacting protein kinase-1","volume":"56","author":"Weinlich","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2022.106051_b0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm3683","article-title":"Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death","volume":"14","author":"Ofengeim","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2022.106051_b0065","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.4049\/jimmunol.1400590","article-title":"Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo","volume":"193","author":"Polykratis","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2022.106051_b0070","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1038\/cddis.2012.176","article-title":"Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models","volume":"3","author":"Takahashi","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2022.106051_b0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41419-019-1735-6","article-title":"Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis","volume":"10","author":"Hou","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2022.106051_b0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13608","article-title":"RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis","volume":"513","author":"Dannappel","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106051_b0085","doi-asserted-by":"crossref","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","article-title":"RIPK1 mediates a disease-associated microglial response in Alzheimer's disease","volume":"114","author":"Ofengeim","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2022.106051_b0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-019-1828-5","article-title":"Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease","volume":"577","author":"Lalaoui","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106051_b0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-019-1830-y","article-title":"A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1","volume":"577","author":"Tao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2022.106051_b0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio711","article-title":"Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury","volume":"1","author":"Degterev","year":"2005","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2022.106051_b0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.str.2013.01.016","article-title":"Structural basis of RIP1 inhibition by necrostatins","volume":"21","author":"Xie","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2022.106051_b0110","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","article-title":"DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors","volume":"59","author":"Harris","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0115","doi-asserted-by":"crossref","first-page":"e00365","DOI":"10.1002\/prp2.365","article-title":"Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers","volume":"5","author":"Weisel","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bioorg.2022.106051_b0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acsmedchemlett.9b00108","article-title":"Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer","volume":"10","author":"Harris","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.106051_b0125","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","article-title":"Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases","volume":"60","author":"Harris","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0130","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1021\/acs.jmedchem.9b00318","article-title":"Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase","volume":"62","author":"Harris","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0135","doi-asserted-by":"crossref","first-page":"114036","DOI":"10.1016\/j.ejmech.2021.114036","article-title":"Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity","volume":"228","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm7011479","article-title":"Identification of Human Intestinal Carboxylesterase as the Primary Enzyme for Activation of a Doxazolidine Carbamate Prodrug","volume":"51","author":"Barthel","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0145","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/jm501371s","article-title":"Organic Carbamates in Drug Design and Medicinal Chemistry","volume":"58","author":"Ghosh","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0150","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/jm300343m","article-title":"Mitigating heterocycle metabolism in drug discovery","volume":"55","author":"Jean","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm2012276","article-title":"Structure-Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"55","author":"Blaser","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0160","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/jm0607653","article-title":"Synthesis and structure-activity relationship for a novel class of potent and selective carbamate-based inhibitors of hormone selective lipase with acute in vivo antilipolytic effects","volume":"50","author":"Ebdrup","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0165","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1021\/acs.jmedchem.1c00432","article-title":"Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl Moiety","volume":"64","author":"Ikeda","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.106051_b0170","doi-asserted-by":"crossref","unstructured":"A. Chen, X. Zhou, S. Tang, M. Liu, X. Wang, evaluation of the inhibition potential of plumbagin against cytochrome p450 using lc-ms\/ms and cocktail approach open, 6 (2016) 180-184.","DOI":"10.1038\/srep28482"},{"key":"10.1016\/j.bioorg.2022.106051_b0175","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1021\/acschemneuro.7b00153","article-title":"Design, Synthesis, and Structure-Activity-Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity","volume":"8","author":"Lu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2022.106051_b0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0042-101032","article-title":"In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats \u2013 A Pilot Study","volume":"82","author":"Bera","year":"2016","journal-title":"Planta Med."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822004576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:36:44Z","timestamp":1758616604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822004576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"alternative-id":["S0045206822004576"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106051","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.106051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106051"}}